|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NDUFC1 |
Gene summary for NDUFC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NDUFC1 | Gene ID | 4717 |
| Gene name | NADH:ubiquinone oxidoreductase subunit C1 | |
| Gene Alias | KFYI | |
| Cytomap | 4q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | O43677 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4717 | NDUFC1 | GSM4909285 | Human | Breast | IDC | 9.69e-03 | -1.35e-01 | 0.21 |
| 4717 | NDUFC1 | GSM4909286 | Human | Breast | IDC | 4.31e-07 | 1.80e-01 | 0.1081 |
| 4717 | NDUFC1 | GSM4909291 | Human | Breast | IDC | 7.41e-09 | 3.78e-01 | 0.1753 |
| 4717 | NDUFC1 | GSM4909294 | Human | Breast | IDC | 1.65e-14 | 1.78e-01 | 0.2022 |
| 4717 | NDUFC1 | GSM4909296 | Human | Breast | IDC | 8.73e-15 | 4.57e-02 | 0.1524 |
| 4717 | NDUFC1 | GSM4909297 | Human | Breast | IDC | 2.17e-18 | -1.37e-01 | 0.1517 |
| 4717 | NDUFC1 | GSM4909298 | Human | Breast | IDC | 1.05e-02 | 2.53e-01 | 0.1551 |
| 4717 | NDUFC1 | GSM4909306 | Human | Breast | IDC | 1.21e-03 | 2.91e-01 | 0.1564 |
| 4717 | NDUFC1 | GSM4909309 | Human | Breast | IDC | 8.42e-04 | -4.60e-03 | 0.0483 |
| 4717 | NDUFC1 | GSM4909311 | Human | Breast | IDC | 2.60e-48 | -4.35e-02 | 0.1534 |
| 4717 | NDUFC1 | GSM4909312 | Human | Breast | IDC | 9.92e-16 | 6.03e-02 | 0.1552 |
| 4717 | NDUFC1 | GSM4909313 | Human | Breast | IDC | 1.88e-06 | 2.51e-02 | 0.0391 |
| 4717 | NDUFC1 | GSM4909315 | Human | Breast | IDC | 2.35e-60 | 8.62e-01 | 0.21 |
| 4717 | NDUFC1 | GSM4909316 | Human | Breast | IDC | 3.64e-33 | 8.26e-01 | 0.21 |
| 4717 | NDUFC1 | GSM4909318 | Human | Breast | IDC | 7.75e-05 | 2.90e-01 | 0.2031 |
| 4717 | NDUFC1 | GSM4909319 | Human | Breast | IDC | 3.54e-67 | 7.35e-02 | 0.1563 |
| 4717 | NDUFC1 | GSM4909320 | Human | Breast | IDC | 3.20e-15 | 2.16e-01 | 0.1575 |
| 4717 | NDUFC1 | GSM4909321 | Human | Breast | IDC | 1.16e-19 | -1.11e-01 | 0.1559 |
| 4717 | NDUFC1 | brca2 | Human | Breast | Precancer | 6.58e-03 | 1.56e-01 | -0.024 |
| 4717 | NDUFC1 | M2 | Human | Breast | IDC | 1.65e-02 | -8.47e-02 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000609112 | Liver | Cirrhotic | generation of precursor metabolites and energy | 238/4634 | 490/18723 | 6.85e-31 | 1.07e-27 | 238 |
| GO:002290012 | Liver | Cirrhotic | electron transport chain | 111/4634 | 175/18723 | 1.94e-27 | 1.52e-24 | 111 |
| GO:004603412 | Liver | Cirrhotic | ATP metabolic process | 144/4634 | 277/18723 | 1.04e-22 | 5.02e-20 | 144 |
| GO:00427737 | Liver | Cirrhotic | ATP synthesis coupled electron transport | 69/4634 | 95/18723 | 1.12e-22 | 5.02e-20 | 69 |
| GO:00427757 | Liver | Cirrhotic | mitochondrial ATP synthesis coupled electron transport | 69/4634 | 95/18723 | 1.12e-22 | 5.02e-20 | 69 |
| GO:00090607 | Liver | Cirrhotic | aerobic respiration | 109/4634 | 189/18723 | 3.88e-22 | 1.62e-19 | 109 |
| GO:00229047 | Liver | Cirrhotic | respiratory electron transport chain | 77/4634 | 114/18723 | 5.84e-22 | 2.29e-19 | 77 |
| GO:00196467 | Liver | Cirrhotic | aerobic electron transport chain | 63/4634 | 87/18723 | 1.04e-20 | 3.43e-18 | 63 |
| GO:00453337 | Liver | Cirrhotic | cellular respiration | 122/4634 | 230/18723 | 2.15e-20 | 6.43e-18 | 122 |
| GO:001598012 | Liver | Cirrhotic | energy derivation by oxidation of organic compounds | 154/4634 | 318/18723 | 3.11e-20 | 8.87e-18 | 154 |
| GO:00061197 | Liver | Cirrhotic | oxidative phosphorylation | 86/4634 | 141/18723 | 6.08e-20 | 1.66e-17 | 86 |
| GO:00331087 | Liver | Cirrhotic | mitochondrial respiratory chain complex assembly | 64/4634 | 93/18723 | 3.85e-19 | 7.79e-17 | 64 |
| GO:00061207 | Liver | Cirrhotic | mitochondrial electron transport, NADH to ubiquinone | 40/4634 | 51/18723 | 1.14e-15 | 1.35e-13 | 40 |
| GO:00102577 | Liver | Cirrhotic | NADH dehydrogenase complex assembly | 42/4634 | 57/18723 | 1.06e-14 | 1.06e-12 | 42 |
| GO:00329817 | Liver | Cirrhotic | mitochondrial respiratory chain complex I assembly | 42/4634 | 57/18723 | 1.06e-14 | 1.06e-12 | 42 |
| GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
| GO:000906012 | Liver | HCC | aerobic respiration | 147/7958 | 189/18723 | 3.13e-23 | 6.61e-21 | 147 |
| GO:004533312 | Liver | HCC | cellular respiration | 171/7958 | 230/18723 | 6.35e-23 | 1.26e-20 | 171 |
| GO:004603422 | Liver | HCC | ATP metabolic process | 198/7958 | 277/18723 | 8.30e-23 | 1.55e-20 | 198 |
| GO:001598022 | Liver | HCC | energy derivation by oxidation of organic compounds | 221/7958 | 318/18723 | 1.02e-22 | 1.86e-20 | 221 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0493216 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
| hsa0472316 | Breast | Precancer | Retrograde endocannabinoid signaling | 25/684 | 148/8465 | 3.05e-04 | 2.47e-03 | 1.89e-03 | 25 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NDUFC1 | SNV | Missense_Mutation | rs781664915 | c.221N>A | p.Gly74Glu | p.G74E | O43677 | protein_coding | deleterious(0.02) | benign(0.383) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4717 | NDUFC1 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
| 4717 | NDUFC1 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 | |
| 4717 | NDUFC1 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |